ANEB-001
Acute Cannabinoid Intoxication / Unintentional Cannabis Poisoning
Phase 2Proof-of-concept established
Key Facts
Indication
Acute Cannabinoid Intoxication / Unintentional Cannabis Poisoning
Phase
Phase 2
Status
Proof-of-concept established
Company
About Anebulo Pharmaceuticals
Anebulo Pharmaceuticals is focused on developing novel therapeutics for substance use disorders, with an immediate priority on acute cannabinoid intoxication. The company has achieved Phase 2 proof-of-concept for its lead candidate, ANEB-001, demonstrating its potential to rapidly reverse THC-induced effects. Anebulo's strategy capitalizes on the urgent, growing medical need created by increasing cannabis legalization and the lack of any approved antidote, positioning it to target emergency department visits and unintentional pediatric poisonings.
View full company profile